Prostate Cancer

William L. Dahut, MD, discusses multiparametric magnetic resonance imaging as an alternative screening technique to prostate-specific antigen testing in prostate cancer.

Leonard G. Gomella, MD, discusses the challenges of genetic testing in prostate cancer.

Neeraj Agarwal, MD, discusses the safety profile of the combination of enzalutamide and talazoparib in patients with metastatic castration-resistant prostate cancer.

The FDA has granted a breakthrough therapy designation to the PARP inhibitor niraparib for the treatment of patients with BRCA1/2–mutant metastatic castration-resistant prostate cancer who have previously received chemotherapy and an androgen receptor inhibitor.

Men who received cabazitaxel (Jevtana) as a third-line systemic agent for metastatic castration-resistant prostate cancer had a significant reduction in radiographic disease progression, leading to a significant increase in overall survival.

Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.

The next-generation androgen receptor apalutamide, in combination with androgen deprivation therapy, demonstrated a 25% reduction in the risk of death compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer in the phase III SPARTAN trial.

Randal H. Henderson, MD, MBA, discusses accessibility of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.

Conflicting guidelines on prostate-specific antigen testing have affected trends on disease presentation and, potentially, the treatment outcomes for many men with this disease. New agents and powerful new imaging tools have added yet more complexity to the decision process. Therefore, more investigation and cooperation on multiple levels is needed to define appropriate standards of care.

Leonard G. Gomella, MD, FACS, discusses the role of genetic testing and emerging biomarkers in prostate cancer.

The FDA has approved apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of radium-223 dichloride (Xofigo) in prostate cancer.